at least one polymer.

A3
B1
cont

15. A method of treating bacterial infections in humans comprising administering to humans in need thereof an antibactericidally effective amount of a composition of claim 10.--

REMARKS

The amendment is submitted to refer to the PCT application, to remove multiple dependency from the claims and to conform the claims to the American practice.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS

Charles A. Muserlian, #19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

CAM:sd
Enclosures: Marked-Up Version of Specification and Claims
Return Receipt Postcard

Spherical agglomerates of telithromycin, their preparation process and their use in the preparation of pharmaceutical forms.

--This application is a 371 of PCT/FR00/02393 filed August 28, 2000.--

A subject of the present invention is spherical agglomerates of telithromycin, their preparation process and their use in the preparation of pharmaceutical forms.

Telithromycin or 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-erythromycin is a product endowed with antibiotic properties of structure:



(I)

described and claimed in European Patent 680967.

The oral route is a preferred form of administration for this product. Some patients, children in particular, have difficulty in swallowing tablets and capsules and therefore it is desirable to have available other forms of administration such as for example oral suspensions, ready to use or prepared extemporaneously at the time of use.

CLAIMS

1) Spherical agglomerates of telithromycin.

2) A Spherical agglomerates of telithromycin ~~according to~~ claim 1, ~~characterized in that~~ wherein the size of the particles is between 30 and 400 microns.

3) A Spherical agglomerates of telithromycin ~~according to~~ claim 2, ~~characterized in that~~ wherein the median size of the particles is ~~situated~~ between 80 and 150 microns.

4) A Spherical agglomerates of telithromycin ~~according to any one of claims 1 to 3, characterized in that~~ of claim 1 wherein the median size of the particles is ~~situated towards~~ about 100 microns.

5) A Process for the preparation of agglomerates ~~according to any one of claims 1 to 4~~, ~~characterized in that~~ claim 1, comprising preparing a suspension of telithromycin crystals ~~is prepared,~~ and Coating these crystals ~~are then coated~~ with a phase insoluble in telithromycin from which telithromycin progressively crystallizes.

6) The ~~Preparation~~ process ~~according to~~ of claim 5, ~~characterized in that~~ wherein a solution of telithromycin in acetone is used.

7) The ~~Preparation~~ process ~~according to~~ of claim 5 ~~or 6~~, ~~characterized in that~~ wherein the crystallization takes place in an acetone/isopropyl ether mixture.

8) The ~~Preparation~~ process ~~according to any one~~ of claims 5 ~~to 7,~~ ~~characterized in that~~ wherein the crystallization is carried out between -5°C and -15°C.

~~9) Spherical agglomerates of telithromycin as obtained by the process according to any one of claims 5 to 8.~~

~~10) Spherical agglomerates of telithromycin according to claim 9, characterized in that the particle size is comprised between 30 and 400 microns.~~

~~11) Spherical agglomerates of telithromycin according to claim 10, characterized in that the median size of the particles is situated between 80 and 150 microns.~~

12) Spherical agglomerates of telithromycin according to any one of claims 9 to 11, characterized in that the median size of the particles is situated towards 100 microns.

13) Use of the spherical agglomerates according to any one of claims 1 to 4 and 9 to 12, characterized in that the spherical agglomerates are surrounded by a layer of polymer in order to obtain the sought galenical form.

AMENDED PAGE